Abstract
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amyotrophic Lateral Sclerosis / drug therapy*
-
Amyotrophic Lateral Sclerosis / metabolism
-
Amyotrophic Lateral Sclerosis / physiopathology
-
Central Nervous System / drug effects*
-
Central Nervous System / metabolism
-
Central Nervous System / physiopathology
-
Coenzymes
-
Dose-Response Relationship, Drug
-
Drug Tolerance / physiology
-
Energy Metabolism / drug effects
-
Energy Metabolism / physiology
-
Female
-
Free Radical Scavengers / administration & dosage
-
Free Radical Scavengers / adverse effects
-
Humans
-
Male
-
Maximum Tolerated Dose
-
Middle Aged
-
Mitochondria / drug effects
-
Mitochondria / metabolism
-
Nerve Degeneration / drug therapy
-
Nerve Degeneration / metabolism
-
Nerve Degeneration / prevention & control*
-
Neurons / drug effects*
-
Neurons / metabolism
-
Neuroprotective Agents / administration & dosage*
-
Neuroprotective Agents / adverse effects
-
Neuroprotective Agents / blood
-
Ubiquinone / administration & dosage
-
Ubiquinone / adverse effects
-
Ubiquinone / analogs & derivatives*
-
Ubiquinone / blood
Substances
-
Coenzymes
-
Free Radical Scavengers
-
Neuroprotective Agents
-
Ubiquinone
-
coenzyme Q10